Aurora Kinase Inhibitor VI ZM447439 (ZM-447439) (CAS: 331771-20-1) is a small molecule inhibitor of Aurora kinases, a family of serine/threonine protein kinases involved in the regulation of cell division and mitosis. It has been investigated as a potential therapeutic agent for cancer, particularly in the treatment of solid tumors and hematological malignancies.
Chemical name: 4-(4-(Dimethylamino)phenyl)-N-(4-(pyridin-3-yl)pyrimidin-2-yl)benzamide)
Molecular formula: C21H20N6O
Formula weight: 368.43 g/mol
CAS No: 331771-20-1
Top ten keywords from Google:
Synonyms:
Health benefits of this product: ZM-447439 has demonstrated potential health benefits in the area of cancer research, particularly in the treatment of solid tumors and hematological malignancies. Its primary mode of action is through the inhibition of Aurora kinases, leading to reduced cell proliferation and increased apoptosis.
Potential effects: ZM-447439 has demonstrated efficacy in several preclinical studies in inhibiting the activity of Aurora kinases, leading to reduced cell proliferation and increased apoptosis in cancer cells. It also has potential benefits for inducing mitotic arrest, reducing angiogenesis (the formation of new blood vessels that can support tumor growth), and inhibiting signal transduction pathways that regulate cell survival and proliferation. ZM-447439 works by disrupting various cellular processes that are necessary for cancer cell survival and growth.
Product mechanism: ZM-447439 works by inhibiting the activity of Aurora kinases, a family of serine/threonine protein kinases involved in the regulation of cell division and mitosis. Aurora kinases play an essential role in regulating chromosome segregation and spindle formation during mitosis. By inhibiting Aurora kinase activity, ZM-447439 can disrupt mitotic checkpoint signaling, leading to reduced tumor growth and increased apoptosis.
Safety: ZM-447439 has been evaluated in several preclinical and clinical trials involving hundreds of participants and has been generally well-tolerated. Rare but potential side effects may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, as well as hematological abnormalities (e.g., decreased white blood cell or platelet counts) and hepatic dysfunction. Patients with liver or kidney disease should exercise caution when taking ZM-447439, as it may affect these conditions. Pregnant or breastfeeding women should avoid using ZM-447439, as its safety in these populations has not been established.
Side effects: Common side effects of ZM-447439 may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. These symptoms are usually mild or moderate and can be managed with supportive care or dose modifications. Less common but more severe side effects may include bleeding disorders, cardiovascular events, and liver or kidney dysfunction, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The optimal dose and dosing regimen of ZM-447439 may vary depending on the patient's condition and treatment goals. In preclinical studies, doses ranging from 10 to 150 mg/kg have been evaluated for various types of cancer. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: Aurora Kinase Inhibitor VI ZM447439 (ZM-447439) (CAS: 331771-20-1) is a small molecule inhibitor of Aurora kinases, a family of serine/threonine protein kinases involved in the regulation of cell division and mitosis. It has been investigated as a potential therapeutic agent for cancer, particularly in the treatment of solid tumors and hematological malignancies. Although it has been generally well-tolerated in preclinical and clinical trials, it may cause some side effects that should be monitored closely. More research is needed to determine its full potential and efficacy in different patient populations and cancer types.
